"Androstenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Unsaturated derivatives of the steroid androstane containing at least one double bond at any site in any of the rings.
| Descriptor ID |
D000736
|
| MeSH Number(s) |
D04.210.500.054.079
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Androstenes".
Below are MeSH descriptors whose meaning is more specific than "Androstenes".
This graph shows the total number of publications written about "Androstenes" by people in this website by year, and whether "Androstenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Androstenes" by people in Profiles.
-
Di Nunno V, Santoni M, Mollica V, Conti A, Montironi R, Battelli N, Ardizzoni A, Massari F. Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. Clin Drug Investig. 2020 Mar; 40(3):211-226.
-
Di Nunno V, Santoni M, Massari F. Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? Lancet Oncol. 2018 09; 19(9):e437.
-
Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018 01; 218(1):68-74.
-
Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol. 2015; 11(21):2881-91.
-
Caffo O, De Giorgi U, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Macrini S, Messina C, Giordano M, Alesini D, Zustovich F, Fraccon AP, Vicario G, Conteduca V, Maines F, Galligioni E. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int. 2015 May; 115(5):764-71.
-
Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec; 114(6):1205-1212.
-
Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005 Dec; 72(6):414-21.
-
Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005 Sep; 106(3):492-501.